Amyotrophic lateral sclerosis Parkinson'
Conditions
Interventions
None listed
Sponsors
Faculty of Medicine, Kitasato University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed as having ALS and satisfying all of the following criteria. 1)ALS patients who are diagnosed by EL Escorial revised Airlie House criteria as clinically definite,clinically probable or clinically probable-laboratory-supported, clinically pssible ALS or clinically suspected ALS, and Stage I, II or III in ALS severity classification. 2)Older than 20 and younger than 71 years old 3)Patients who give informed consent after detailed explanation of the study As disease controls, PD or MS patients satisfying all of the following criteria. 1)Older than 20 and younger than 71 years old 2)Patients who consulted a nerve outpatient and obtained consent for study entry 3)Patients who give informed consent after detailed explanation of the study Healthy individuals satisfying all of the following criteria. 1)Older than 20 and younger than 71 years old 2)Healthy individuals who have interest in this study 3)Healthy individuals who give informed consent after detailed explanation of the study
Exclusion criteria
Exclusion criteria: 1)Patient to whom the diagnosis has not been disclosed 2)Patient having severe psychiatric symptoms (hallucination, delusion) or dementia 3)Patient having serious orthostatic hypotension or other types of hypotension 4)Patient having a severe complication(s) such as heart, kidney and/or liver disease 5)Patient having the complications of the allergic disease that an acidophile level is easy to rise 6)Patient did not have ability to comprehend informed consent 7)Patient who was inappropriate for this study 8)Patient who has received an investigational drugs or devices within three months before 9) Patient who participates in other clinical trials *The patient treated with existing therapeutic drug does not correspond to exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exploration of novel biomarker | — |
Countries
Japan
Contacts
Public ContactKazunori Tanaka
Faculty of Medicine, Kitasato University Department of Molecular Neurology
Outcome results
None listed